Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of OSI Pharmaceuticals, Inc. (“OSI” or the “Company”) (Nasdaq: OSIP) relating to the takeover bid by Astellas Pharma, Inc (“Astellas”). Under the terms of the offer, OSI shareholders would receive $52.00 for each share of OSI stock they own.

The investigation concerns possible breaches of fiduciary duty and other violations of state law related to the OSI board’s actions. The OSI board allegedly rejected an earlier takeover proposal from Astellas that would have paid OSI shareholders a 50% premium to the prior day’s closing price.

If you own shares of OSI and wish to discuss the legal ramifications of the proposed offer, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, or by calling toll free 877-LEGAL-90.

Copyright Business Wire 2010